| Matthew Mackay, PSYD | |
|
1380 E Medical Center Dr Ste 3100, St George, UT 84790-2135 | |
| (435) 251-2740 | |
| Not Available |
| Full Name | Matthew Mackay |
|---|---|
| Gender | Male |
| Speciality | Clinical Psychologist |
| Experience | 17 Years |
| Location | 1380 E Medical Center Dr Ste 3100, St George, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619160645 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | PSY25080 (California) | Secondary |
| 103TC0700X | Psychologist - Clinical | 376697 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer and rare disease patients, and its collaborators announced the publication in Cancer Cell of breakthrough research in the treatment of MLL-rearranged leukemia (MLL), a genetically-defined subset of acute lymphoblastic leukemia and acute myelogenous leukemia.
Pfizer Inc. today announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter brand for heart attack prevention in Poland, from ZF Polpharma SA.
Talecris Biotherapeutics, Inc. (TLCR) announced today that it has been granted orphan drug designation by the European Commission for the development of Plasmin (human) to treat acute peripheral arterial occlusion (aPAO). Talecris is currently investigating Plasmin in a phase II clinical trial designed to assess its ability to treat aPAO, a condition in which arterial blood flow to the extremities, usually the legs, is blocked by a clot.
McMaster University researchers have discovered a new drug target that may be effective at preventing the onset of Huntington's disease, working much the same way heart medications slow the progression of heart disease and reduce heart attacks.
Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its clinical development of ALT-801, a novel tumor-targeted immunotherapeutic designed to improve the efficacy and safety of the FDA-approved anticancer cytokine, interleukin-2 (IL-2).
› Verified 4 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer and rare disease patients, and its collaborators announced the publication in Cancer Cell of breakthrough research in the treatment of MLL-rearranged leukemia (MLL), a genetically-defined subset of acute lymphoblastic leukemia and acute myelogenous leukemia.
Pfizer Inc. today announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter brand for heart attack prevention in Poland, from ZF Polpharma SA.
Talecris Biotherapeutics, Inc. (TLCR) announced today that it has been granted orphan drug designation by the European Commission for the development of Plasmin (human) to treat acute peripheral arterial occlusion (aPAO). Talecris is currently investigating Plasmin in a phase II clinical trial designed to assess its ability to treat aPAO, a condition in which arterial blood flow to the extremities, usually the legs, is blocked by a clot.
McMaster University researchers have discovered a new drug target that may be effective at preventing the onset of Huntington's disease, working much the same way heart medications slow the progression of heart disease and reduce heart attacks.
Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its clinical development of ALT-801, a novel tumor-targeted immunotherapeutic designed to improve the efficacy and safety of the FDA-approved anticancer cytokine, interleukin-2 (IL-2).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Mackay, PSYD Po Box 27128, Salt Lake City, UT 84127-0128 Ph: (435) 251-2740 | Matthew Mackay, PSYD 1380 E Medical Center Dr Ste 3100, St George, UT 84790-2135 Ph: (435) 251-2740 |
News Archive
Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer and rare disease patients, and its collaborators announced the publication in Cancer Cell of breakthrough research in the treatment of MLL-rearranged leukemia (MLL), a genetically-defined subset of acute lymphoblastic leukemia and acute myelogenous leukemia.
Pfizer Inc. today announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter brand for heart attack prevention in Poland, from ZF Polpharma SA.
Talecris Biotherapeutics, Inc. (TLCR) announced today that it has been granted orphan drug designation by the European Commission for the development of Plasmin (human) to treat acute peripheral arterial occlusion (aPAO). Talecris is currently investigating Plasmin in a phase II clinical trial designed to assess its ability to treat aPAO, a condition in which arterial blood flow to the extremities, usually the legs, is blocked by a clot.
McMaster University researchers have discovered a new drug target that may be effective at preventing the onset of Huntington's disease, working much the same way heart medications slow the progression of heart disease and reduce heart attacks.
Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its clinical development of ALT-801, a novel tumor-targeted immunotherapeutic designed to improve the efficacy and safety of the FDA-approved anticancer cytokine, interleukin-2 (IL-2).
› Verified 4 days ago
Dr. Christina J Durham, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 166 N 300 W, Suite 1, St George, UT 84770 Phone: 435-688-9471 Fax: 435-688-9478 | |
Tim R Kockler, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1224 S. River Road, Suite 221, St George, UT 84790 Phone: 435-632-1445 Fax: 435-688-1091 | |
David Brent Tate, PH.D. Psychologist Medicare: May Accept Medicare Assignments Practice Location: 321 N Mall Dr, Suite I-201, St George, UT 84790 Phone: 435-656-0506 Fax: 435-272-4009 | |
Dr. Virgil W. Brockbank, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2480 Red Cliffs Dr, St George, UT 84790 Phone: 435-673-6446 Fax: 435-652-8020 | |
Paul Staheli, PHD Psychologist Medicare: Medicare Enrolled Practice Location: 474 W 200 N, Suite 100, St George, UT 84770 Phone: 435-634-5600 Fax: 435-986-8700 | |
Allen Garrett, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 474 W 200 N, St George, UT 84770 Phone: 435-634-5600 | |
Chauncey Sandberg Adams, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 544 S 400 E, St George, UT 84770 Phone: 435-688-4343 |